Published :
Tables : 48
Figures : 47
Category : Healthcare
No. of Pages : 235
Report Code : HC-U3305
Human papillomavirus (HPV) Vaccines Market is poised to value USD 8839 million by 2028 end at a CAGR of 12.4% during the forecast period 2022 to 2028. Human papillomavirus (HPV) transmission occurs when individuals with similar skin tones interact. Your genital area, mouth, or neck may be affected by HPV, which is spread through sexual activity. The Centers for Disease Control and Prevention (CDC) report that HPV is the most frequent infection. Despite having few sexual partners, most people who engage in sexual activity will eventually contract one or more of its variants. There may be no negative health effects from some genitourinary HPV infections. Certain HPV subtypes, however, have been linked to neck, uterine, and even anus malignancies. The human papillomavirus vaccine is used to treat people who have a viral infection that was contracted through skin-to-skin contact. An additional sexually transmitted infection is the human papillomavirus (HPV). The herpes virus, often known as HSV and HIV, is different from the HPV virus. The human papillomavirus (HPV) vaccine shields the body from numerous types of infection. The rising demand for HPV vaccinations is likely to be the main driver of the global market potential for human papillomavirus vaccines during the forecast period due to the rising prevalence of HPV-related disorders. Bivalent, quadrivalent, and nonavalent vaccinations are the only kind available on the market. The approval of novel HPV vaccines and rising government and private organisation activities for early screening and vaccination are the main drivers of the market for human papillomavirus (HPV) vaccinations. In the upcoming years, the market is expected to experience healthy expansion as a result of factors including the rising prevalence of HPV-associated malignancies such anal, oropharynx, and genital parts cancers and the rising need for HPV vaccines to help prevent infections. FutureWise Market Research has instantiated a report that provides an intricate analysis of Human Papillomavirus (HPV) Vaccines Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Human Papillomavirus (HPV) Vaccines Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Market Segmentation: By Type • Bivalent • Polyvalent By Disease Indication • HPV Associated Cancer • Genital Warts By Distribution Channel • Hospitals and Retail Pharmacies • Retail Pharmacies • Government Suppliers • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Human papillomavirus (HPV) Vaccines Market Sample Video: The market is categorised into type, disease indication, distribution channel and region. The type segment is divided into bivalent and polyvalent. The disease indication segment is classified into HPV associated cancer and genital warts. The HPV associated cancer is predicted to account the largest human papillomavirus vaccines market share owing to the rising prevalence of cervical cancers in countries with the largest youth population. The distribution channel segment is bifurcated into hospitals and retail pharmacies, government suppliers and others. The hospital and retail pharmacy segment is anticipated to lead the market owing to advancements in healthcare infrastructure and increasing number of HPV patient population across the word. Regional Analysis: The North America region is predicted to dominate the market during the forecast period owing to growing investments in research and development of advanced HPV vaccines along with a strong presence of key market players in the region. Merck, for instance, produced Gardasil in 2006 which could prevent infection from four HPV strains- 6,11, 16 and 18. Gardasil 9, as of 2017 is the only available HPV vaccine in the United States which was approves by FDA in December 2014. Such a limited availability of HPV vaccines has paved way for key players to conduct research activities for developing newer vaccines in the region. Competitive Landscape: The key players of the market associated are Merck Co., Inc., Glaxosmithkline Plc. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global human papillomavirus (HPV) vaccines market by type, by disease indication, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Human papillomavirus (HPV) transmission occurs when individuals with similar skin tones interact. Your genital area, mouth, or neck may be affected by HPV, which is spread through sexual activity. The Centers for Disease Control and Prevention (CDC) report that HPV is the most frequent infection. Despite having few sexual partners, most people who engage in sexual activity will eventually contract one or more of its variants. There may be no negative health effects from some genitourinary HPV infections. Certain HPV subtypes, however, have been linked to neck, uterine, and even anus malignancies. The human papillomavirus vaccine is used to treat people who have a viral infection that was contracted through skin-to-skin contact. An additional sexually transmitted infection is the human papillomavirus (HPV). The herpes virus, often known as HSV and HIV, is different from the HPV virus. The human papillomavirus (HPV) vaccine shields the body from numerous types of infection. The rising demand for HPV vaccinations is likely to be the main driver of the global market potential for human papillomavirus vaccines during the forecast period due to the rising prevalence of HPV-related disorders. Bivalent, quadrivalent, and nonavalent vaccinations are the only kind available on the market. The approval of novel HPV vaccines and rising government and private organisation activities for early screening and vaccination are the main drivers of the market for human papillomavirus (HPV) vaccinations. In the upcoming years, the market is expected to experience healthy expansion as a result of factors including the rising prevalence of HPV-associated malignancies such anal, oropharynx, and genital parts cancers and the rising need for HPV vaccines to help prevent infections.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Human Papillomavirus (HPV) Vaccines Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Human Papillomavirus (HPV) Vaccines Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Market Segmentation:
By Type • Bivalent • Polyvalent By Disease Indication • HPV Associated Cancer • Genital Warts By Distribution Channel • Hospitals and Retail Pharmacies • Retail Pharmacies • Government Suppliers • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Human papillomavirus (HPV) Vaccines Market Sample Video:
The market is categorised into type, disease indication, distribution channel and region. The type segment is divided into bivalent and polyvalent. The disease indication segment is classified into HPV associated cancer and genital warts. The HPV associated cancer is predicted to account the largest human papillomavirus vaccines market share owing to the rising prevalence of cervical cancers in countries with the largest youth population. The distribution channel segment is bifurcated into hospitals and retail pharmacies, government suppliers and others. The hospital and retail pharmacy segment is anticipated to lead the market owing to advancements in healthcare infrastructure and increasing number of HPV patient population across the word.
Regional Analysis:
The North America region is predicted to dominate the market during the forecast period owing to growing investments in research and development of advanced HPV vaccines along with a strong presence of key market players in the region. Merck, for instance, produced Gardasil in 2006 which could prevent infection from four HPV strains- 6,11, 16 and 18. Gardasil 9, as of 2017 is the only available HPV vaccine in the United States which was approves by FDA in December 2014. Such a limited availability of HPV vaccines has paved way for key players to conduct research activities for developing newer vaccines in the region.
Competitive Landscape:
The key players of the market associated are Merck Co., Inc., Glaxosmithkline Plc.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global human papillomavirus (HPV) vaccines market by type, by disease indication, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Human Papillomavirus (HPV) Vaccines Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Human Papillomavirus (HPV) Vaccines Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Human Papillomavirus (HPV) Vaccines Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Human Papillomavirus (HPV) Vaccines Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Bivalent 7.2. Polyvalent 8. Human Papillomavirus (HPV) Vaccines Market, By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. HPV Associated Cancer 8.2. Genital Warts 9. Human Papillomavirus (HPV) Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals and Retail Pharmacies 9.2. Retail Pharmacies 9.3. Government Suppliers 9.4. Others 10. North America Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Merck Co., Inc. 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Glaxosmithkline Plc 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Human Papillomavirus (HPV) Vaccines Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Human Papillomavirus (HPV) Vaccines Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Human Papillomavirus (HPV) Vaccines Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Human Papillomavirus (HPV) Vaccines Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Bivalent 7.2. Polyvalent
8. Human Papillomavirus (HPV) Vaccines Market, By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. HPV Associated Cancer 8.2. Genital Warts
9. Human Papillomavirus (HPV) Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals and Retail Pharmacies 9.2. Retail Pharmacies 9.3. Government Suppliers 9.4. Others
10. North America Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Human Papillomavirus (HPV) Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Merck Co., Inc. 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Glaxosmithkline Plc 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics